Key result
Paclitaxel-eluting stents for unprotected LMCA disease show ~36% MACE incidence at four years.
Cohort (n=93)
Treatment of unprotected LMCA disease with paclitaxel-eluting stents demonstrates acceptable long-term safety with low cardiac mortality, though the high rate of target lesion revascularization highlights the need for more effective strategies, particularly for distal LMCA disease.
High MACE and TLR rates caution against paclitaxel-eluting stents for unprotected LMCA; leaves open randomized comparisons with contemporary devices.
No takes yet. Share an insight, caveat, or question.
Godino et al. (2010) conducted a cohort in Unprotected left main coronary artery (LMCA) disease (n=93). Paclitaxel-eluting stent (PES) implantation was evaluated on Overall incidence of MACE. Paclitaxel-eluting stent implantation for unprotected LMCA disease resulted in a 35.5% incidence of MACE and a 25.8% target lesion revascularization rate at a median follow-up of 1,450 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: